The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...

BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Ford is one of the many stocks on this list of the best dividend stocks in the S&P 500 that have seen shares slump lately.

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are ...

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are ...